Hoth Therapeutics, Inc. 8-K

What Happened

• Hoth Therapeutics, Inc. announced on April 1, 2026 that it entered into a securities purchase agreement and closed the offering on April 2, 2026. The company sold 2,857,144 shares of common stock at $0.70 per share (gross proceeds ~ $2.0 million) under its S-3 shelf (effective Dec. 4, 2025).
• In a concurrent private placement, the investors received unregistered warrants to buy one share per warrant at $0.85 per share, exercisable beginning six months after issuance for five years. The warrants may be exercised on a cashless basis if the underlying shares are not registered for resale.

Key Details

• Shares sold: 2,857,144 at $0.70 per share; gross proceeds ≈ $2.0M (before fees/expenses).
• Warrants: one warrant per share, $0.85 exercise price, exercisable six months after issuance for five years; cashless exercise permitted if no registration.
• Beneficial ownership cap: warrant exercise blocked to prevent holder (with affiliates) exceeding 4.99% ownership (waivable to 9.99% with 61 days’ notice).
• Placement agent (H.C. Wainwright): 7.0% cash fee + 1.0% management fee of gross proceeds, plus warrants to purchase up to 5% of shares sold (142,857 warrants) at $0.875 each; plus specific expense payments (~$70,950 total disclosed fees/expenses).

Why It Matters

• This transaction provides Hoth with immediate liquidity (about $2M before fees) to use for working capital and general corporate purposes.
• The issuance of warrants can lead to future share dilution if exercised; exercise timing and beneficial ownership limits may affect when/if that dilution occurs.
• The company suspended its prior ATM prospectus supplement and will not use that ATM facility until a new prospectus supplement is filed, which may limit near‑term equity flexibility.
• Securities were sold relying on exemptions for private placements (Section 4(a)(2) and Rule 506), so the warrants and related shares are unregistered for resale unless and until registered.